Tivic Health Systems

Tivic Health Systems, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company was founded by Jennifer Ernst and John Claude on September 22, 2016 and is headquartered in Hayward, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tivic Health Systems reports revenue growth and strategic advancements in Q1 2024

Tivic Health Systems showcased revenue growth and strategic initiatives in their Q1 2024 earnings call, emphasizing progress in bioelectronic medicine and clinical studies.
While facing challenges in managing a net loss and optimizing sales dynamics, the company's strengths lie in fiscal responsibility, product innovation, and market expansion.
Opportunities abound for Tivic Health to capitalize on their VNS program success, ClearUp product momentum, and strategic funding for future growth and value creation.
By balancing financial discipline with innovation, Tivic Health aims to navigate challenges, leverage strengths, and seize opportunities for sustainable growth and market leadership.

Tivic Health Systems advances VNS technology amidst financial challenges

Tivic Health Systems is making strides in VNS technology development and clinical research, despite facing financial and compliance challenges. With a strong patent portfolio and a focus on innovation, the company is well-positioned to capitalize on emerging opportunities in the medical device market.

Tivic Health Systems navigates challenges, eyes growth in VNS market

Tivic Health Systems faces financial challenges but shows resilience through strategic focus on profitability, innovation, and operational efficiency.
The company's progress in the VNS program and market assessment efforts position it well for future growth and market expansion opportunities.
With a new CFO onboard and a proactive approach to addressing product challenges, Tivic Health is poised to navigate challenges and capitalize on growth prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tivic Health Systems, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company was founded by Jennifer Ernst and John Claude on September 22, 2016 and is headquartered in Fremont, CA.

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. ("Tivic", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its public offering of an aggregate of 4,710,000 shares of its common stock, Series A warrants to purchase up to 4,710,000 shares of common stock and Series B warrants to purchase up to 7,065,000 shares of common stock, at a public offering price of $0.85 per share and accompanying warrants. The Series.

Tivic Health Announces Pricing of $4.0 Million Public Offering

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today the final results of their pilot research study with The Feinstein Institutes for Medical Research at Northwell Health. Through this collaboration, Tivic Health has confirmed the effectiveness of its patent-pending non-invasive cervical vagus nerve stimulation (ncVNS) approach, which induces responses in the au.

Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (VNS); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems

Tivic Health Systems, Inc. (TIVC) Q4 2023 Earnings Call Transcript

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2023. Tivic's commercial platform is a handheld design that interfaces non-invasively with the trigeminal, sympathetic, and other facial and cranial nerve structures. This platform is the basis for Tivic's existing product, currently marketed with FDA approval as.

Tivic Reports Fiscal Year 2023 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”) (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its year-end financial results for 2023 via pre-recorded conference call and webcast on Monday, March 25, 2024 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 434944 Webcast Link https://www.webcaster4.com/Webc.

Tivic Health to Report 2023 Year-End Financial Results on March 25th Via Conference Call and Webcast

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that enrollment in its pilot clinical study of a proprietary approach to non-invasive vagus nerve stimulation (VNS) has been completed. VNS is a growing market that is part of the $8.3B global neurostimulation market, which has a projected CAGR of 12.2%, according to Global Market Insights. Implanted VNS is currently.

Tivic Health Announces Completion of Enrollment for Study of Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has entered a limited exclusive distribution agreement with one of the Top 10 Medical Equipment Distributors and Suppliers in the nation. Under the terms of the agreement, the new Distributor will have certain exclusive distribution rights for Tivic Health's ClearUP product for Walmart, Target, eBay and Kroger.

Tivic Enters Exclusive Distribution Agreement with Top 10 Medical Product Distributor for Mass Market Retail

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, announced today the launch of the second generation of Tivic ClearUP. The new and improved Tivic ClearUP 2.0, now with a new chip for power management for faster charge and longer battery life, is available starting today on TivicHealth.com. ClearUP 2.0 is a clinically proven way to clear congestion and reliev.

Tivic Health Announces Launch of New and Improved ClearUP 2.0

Tivic Health Systems, Inc. (TIVC) came out with a quarterly loss of $1.48 per share versus the Zacks Consensus Estimate of a loss of $7. This compares to loss of $27 per share a year ago.

Tivic Health Systems, Inc. (TIVC) Reports Q3 Loss, Misses Revenue Estimates

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the third quarter 2023 ended September 30, 2023 (“Q3 2023”). Third Quarter 2023 Financial Highlights Revenue for Q3 2023 was $282 thousand, compared to $161 thousand for Q2 2023 and $477 thousand in Q3 2022. Gross profit was $108 thousand, compared to $63 thousand in Q3 2022, an increase of 71%. Gr.

Tivic Reports Third Quarter 2023 Financial Results

Tivic Health (NASDAQ: TIVC ) stock is taking off on Monday as investors are hopeful about the health technology company's upcoming earnings report. Tivic Health is set to release its earnings report for the third quarter of 2023 after markets close on Tuesday.

Why Is Tivic Health (TIVC) Stock Up 63% Today?

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the third quarter 2023 via pre-recorded conference call and webcast on Tuesday, November 14th, 2023 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 302318 Webcast Link https://www.webcaster.

Tivic Health to Report Third Quarter 2023 Financial Results on November 14th Via Conference Call and Webcast

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has signed an agreement with InStep Health® to introduce the Company's bioelectronic sinus device, ClearUP®, to over 2,500 healthcare providers (HCP) and their patients. InStep Health assists pharmaceutical, OTC, and consumer-packaged brands to reach consumers at the center of care, whether in the doctor's off.

Tivic Health Partners With InStep Health to Access Over 2,500 Healthcare Providers and Their Patients.

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC) (“Tivic” or the “Company”), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, announced today that it has received notice from The NASDAQ Stock Market LLC (NASDAQ) informing Tivic that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market and that it is in compliance with.

Tivic Health Systems, Inc. Regains Compliance With Nasdaq Listing Requirements

Tivic Health Systems (NASDAQ: TIVC ) stock is rocketing higher on Tuesday despite a lack of news this morning. However, one thing that investors will note is the health technology company's shares seeing heavy trading today.

Why Is Tivic Health Systems (TIVC) Stock Up 112% Today?

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that the Company has entered into a non-exclusive agreement with AmerisourceBergen, soon to be Cencora, to make Tivic's products available on AmerisourceBergen's third-party marketplace. Tivic's patented ClearUP bioelectronic sinus pain relief device will be offered on AmerisourceBergen Marketplace, the com.

Tivic Health Signs Agreement with AmerisourceBergen for Retail Pharmacy Customers

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC) (“Tivic” or the “Company), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, announced today that its Board of Directors has declared a 1-for-100 reverse stock split of the company's issued and outstanding shares of common stock. The reverse stock split will become effective on August 23, 2023 (the “Effective Date”) at 12:01 AM Eastern Time. The company's comm.

Tivic Health Systems, Inc. Announces Reverse Stock Split

Tivic Health Systems (NASDAQ: TIVC ) stock is rocketing higher on Thursday after getting started on a new clinical trial. According to a press release from the company, its study at The Feinstein Institutes for Medical Research has been given approval by the Institutional Review Board.

Why Is Tivic Health Systems (TIVC) Stock Up 45% Today?

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that the research study that the company is funding at The Feinstein Institutes for Medical Research has received study approval from the Institutional Review Board (“IRB”) and has initiated study recruitment and enrollment for its novel non-invasive bioelectronic device approach to vagus nerve stimulation. An IRB is.

Tivic Health Funded Study Begins Enrollment for Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the second quarter of 2023 ended June 30, 2023 (“Q2 2023”). Second Quarter 2023 Financial Summary Gross profit of 37.5% in the second quarter of 2023, compared to 23.4% in the second quarter of 2022, on total revenue of $60 thousand in the second quarter of 2023 from $123 thousand in the second qua.

Tivic Reports Second Quarter 2023 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the first quarter of 2023 via pre-recorded conference call and webcast on Monday, August 14th, 2023 at 1:30 pm PT / 4:30 pm ET. Teleconference Details: Toll-Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 679005 Webcast Link https://www.webcaster.

Tivic Health Reports Second Quarter 2023 Financial Results on August 14th Via Conference Call and Webcast

Tivic Health Systems (NASDAQ: TIVC ) stock is falling hard on Monday after the health technology company priced a public share offering. According to a press release, the company is offering up 33,173,000 shares of TIVC stock for a price of $0.041 per share.

Why Is Tivic Health Systems (TIVC) Stock Down 44% Today?

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its previously announced public offering of 33,173,000 shares of its common stock at a public offering price of $0.041 per share. Gross proceeds from the offering are expected to be approximately $1.4 million before deducting placement agent fees and estimated offering expenses. Tivic intends.

Tivic Health Announces Pricing of $1.4 Million Public Offering of Common Stock

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it intends to offer and sell shares of its common stock in a public offering. All of the shares of common stock are being offered by Tivic. Tivic intends to use the net proceeds of the offering, if any, for working capital and general corporate purposes. Consummation of the offering is subject to market an.

Tivic Health Announces Proposed Public Offering of Common Stock

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that the U.S. Patent and Trademark Office has issued its sixth patent for its bioelectronic platform, expanding the Company's intellectual property to include the proprietary contacts, conductive circuitry design, and algorithms to optimize therapy delivery. “This patent issuance continues to build the strength of our.

News for Tivic Health Systems Stock (TIVC)